NCT03732950: Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer
- State
- Under way
- Phase
- Phase 2
- People
- 5 taking part
- Started
- 6 Mar 2019
- Primary completion
- 5 Dec 2023
- Arms
- Treatment (pembrolizumab)
- Results
- None posted
- 7 Nov 2018: Trial registered
- 6 Mar 2019: Trial started